Compare Monolithic Power Systems Inc (MPWR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Monolithic Power Systems Inc trades at $1,424 (market cap $68.90B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Monolithic Power Systems Inc pays a 0.57% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| MPWR | XBI | |
|---|---|---|
Market Cap | $68.90B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $1.69K | $164.28 |
52-Week Low | $820.74 | $86.92 |
Enterprise Value | $67.51B | — |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,425.01, up 3.18% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, supported by AI-driven revenue growth. Recent news highlights legal scrutiny but also analyst optimism post-Q2 results.
Outlook is positive with an 88% buy rating from analysts and a $1,870 consensus price target, though high valuation ratios and competitive risks warrant caution. Upside hinges on continued AI infrastructure demand, while downside risks include execution challenges and market volatility.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
